

# St. Boniface Hospital Research

## Neuroscience Seminar Series

Hosted by the Division of Neurodegenerative Disorders

Friday, February 28<sup>th</sup> 2014

12:00 Noon

500 John Buhler Research  
Centre - Bannatyne Campus



Everyone is invited to attend!



co-hosted by Manitoba Institute of Child Health

For more information contact  
DND Office: (T) 204.235.3939 or  
(E) [dnd@sbrc.ca](mailto:dnd@sbrc.ca)

## Dr. Bruce Perkins

Associate Professor, Division of Endocrinology and Metabolism  
University of Toronto & Clinician Scientist, Lunenfeld Tanenbaum  
Research Institute, Leadership Sinai Centre for Diabetes,  
Mount Sinai Hospital

### Topic: The Identification of Diabetic Neuropathy in type 1 Diabetes

**Brief Biosketch:** Bruce A Perkins, MD MPH is Associate Professor and Endocrinologist at the University of Toronto, and a Diabetes Complications Clinician-Scientist. He obtained his MD and Internal Medicine training at the University of Toronto, his endocrinology subspecialty training at Harvard University, his Masters of Public Health in Epidemiology at the Harvard School of Public Health, and a research fellowship in epidemiology at the Joslin Diabetes Center. In 2003 he was appointed at the Toronto General Hospital and earned a Canadian Diabetes Association early career personnel award for his work in diabetic neuropathy.

His clinical practice has focused on type 1 diabetes management, and he directed the formation of an insulin pump program at the UHN. His research work has focused on clinical biomarkers for the early stages of diabetes complications using longitudinal cohort methods as well as clinical trials. Highlights are “Early GFR Loss” as a predictive marker for risk of advanced kidney disease using serial cystatin C analysis and the concept of in-vivo Corneal Confocal Microscopy as a method to analyze the small fiber morphological abnormalities that predict diabetic neuropathy. His clinical trial work in insulin pump and continuous glucose monitoring interventions has contributed to refinements in type 1 diabetes care. He is active on national and international diabetes clinical practice guideline committees including Microvascular Chair on the CDA’s 2013 Clinical Practice Guidelines Steering Committee. He has received funding from the Juvenile Diabetes Research Foundation, Canadian Diabetes Association, CIHR, and the Banting and Best Diabetes Center and is a member of the JDRF’s Canadian Clinical Trial Network. He is initiating a JDRF-funded nation-wide cohort study to determine factors associated with longevity in type 1 diabetes.